Certified by Founder Lodge
Third Rock Ventures
United States - Boston, MA
INVESTOR
1 Disclosed Funding Rounds $200,000,000
40 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
We discover, launch and build great companies based on bold ideas that meet at the intersection of science, strategy, business and medicine – where transformational science meets operational
| Company | Date | Round | Raised |
|---|---|---|---|
 Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
 Flare Therapeutics |
March, 23 ,2023 | Series B | $123,000,000 |
 Septerna |
July, 18 ,2023 | Series B | $150,000,000 |
 ARTBIO |
December, 08 ,2023 | Series A | $90,000,000 |
| Septerna |
July, 18 ,2023 | Series B | $150,000,000 |
| ARTBIO |
December, 08 ,2023 | Series A | $90,000,000 |
 CARGO Therapeutics |
March, 06 ,2023 | Series A | $200,000,000 |
 Rapport Therapeutics |
March, 08 ,2023 | Series A | $100,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
 Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| ARTBIO |
December, 08 ,2023 | Series A | $90,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| ARTBIO |
December, 08 ,2023 | Series A | $90,000,000 |
| Flare Therapeutics |
March, 23 ,2023 | Series B | $123,000,000 |
| Rapport Therapeutics |
March, 08 ,2023 | Series A | $100,000,000 |
 Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Septerna |
July, 18 ,2023 | Series B | $150,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
 Merida Biosciences |
April, 10 ,2025 | Series A | $121,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| Flare Therapeutics |
March, 23 ,2023 | Series B | $123,000,000 |
| ARTBIO |
December, 08 ,2023 | Series A | $90,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Septerna |
July, 18 ,2023 | Series B | $150,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| Merida Biosciences |
April, 10 ,2025 | Series A | $121,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| Merida Biosciences |
April, 10 ,2025 | Series A | $121,000,000 |
| ARTBIO |
December, 08 ,2023 | Series A | $90,000,000 |
 Corvia Medical, Inc. |
June, 18 ,2025 | Unknown | $55,000,000 |
| Asher Biotherapeutics |
April, 17 ,2024 | Series C | $55,000,000 |
| Marea Therapeutics |
June, 20 ,2024 | Series A | $190,000,000 |
| Maze Therapeutics |
December, 04 ,2024 | Series D | $115,000,000 |
| Merida Biosciences |
April, 10 ,2025 | Series A | $121,000,000 |
| Corvia Medical, Inc. |
June, 18 ,2025 | Unknown | $55,000,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
